Patents by Inventor Simone ALIDORI

Simone ALIDORI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20250099464
    Abstract: The present invention relates to Human Immunodeficiency Virus (HIV) prevention and treatment. In particular, the invention relates to a pharmaceutical composition comprising: cabotegravir; a wetting agent; a stabilizer; and a tonicity adjuster; wherein cabotegravir is present in the form of particles having a mass median diameter (X50) of between (and including) 2.5 ?m and 10 ?m.
    Type: Application
    Filed: September 25, 2024
    Publication date: March 27, 2025
    Applicant: ViiV Healthcare UK (No.3) Limited
    Inventors: Kevin Sam Chu, Clinton Frank Jones, Deepak Balkrishna Mundhra, Rennan Pan, Austin Philip, Simone Alidori, Manish Kumar Gupta, Pratik Saha, Pranjal Sameer Taskar
  • COMBINATION OF CABOTEGRAVIR AND LEVONORGESTREL
    Publication number: 20230321089
    Abstract: The present invention relates to a combination formulation of antiretroviral pharmaceutical compositions and contraceptive agents for the treatment or prevention of human immunodeficiency virus (HIV) and the prevention of pregnancy, the composition comprising an effective amount of Cabotegravir and an effective amount of a contraceptive agent. The present invention also provides a method of preventing pregnancy and treating or preventing HIV in a human by administering a therapeutically effective amount of Cabotegravir and an effective amount of a contraceptive agent to the human.
    Type: Application
    Filed: August 30, 2021
    Publication date: October 12, 2023
    Inventors: Nima AKHAVEIN, Simone ALIDORI, Emile Johann VELTHUISEN
  • METHOD AND COMPOSITION FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS
    Publication number: 20220280424
    Abstract: Pharmaceutical compositions for preventing or reducing kidney injury are disclosed, where the pharmaceutical compositions include (1) siRNAs non-covalently conjugated to functionalized single walled carbon nanotubes (f-SWCNTs) and (2) a pharmaceutically acceptable carrier, where the siRNAs inhibit expression of one or more genes selected from the group consisting of MEP1B and p53 genes.
    Type: Application
    Filed: October 27, 2021
    Publication date: September 8, 2022
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Michael R. MCDEVITT, Simone ALIDORI, Nima AKHAVEIN, David A. SCHEINBERG
  • Method and composition for targeted delivery of therapeutic agents
    Patent number: 11185501
    Abstract: Functionalized single walled or multi-walled carbon nanotubes (f-CNTs) can be delivered into mammals to targeted organs, such as the kidney and the liver. These f-CNTs may be non-covalently linked or covalently linked to therapeutic agents. In particular, the application delivers carbon nanotube-therapeutic agent conjugates to a target organ, thereby preventing or reducing damages to the organ caused by other agents or procedure.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: November 30, 2021
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Michael R. McDevitt, Simone Alidori, Nima Akhavein, David A. Scheinberg
  • METHOD AND COMPOSITION FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS
    Publication number: 20200237663
    Abstract: Functionalized single walled or multi-walled carbon nanotubes (f-CNTs) can be delivered into mammals to targeted organs, such as the kidney and the liver. These f-CNTs may be non-covalently linked or covalently linked to therapeutic agents. In particular, the application delivers carbon nanotube-therapeutic agent conjugates to a target organ, thereby preventing or reducing damages to the organ caused by other agents or procedure.
    Type: Application
    Filed: October 11, 2019
    Publication date: July 30, 2020
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Michael R. MCDEVITT, Simone ALIDORI, Nima AKHAVEIN, David A. SCHEINBERG
  • METHOD AND COMPOSITION FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS
    Publication number: 20170348234
    Abstract: Functionalized single walled or multi-walled carbon nanotubes (f-CNTs) can be delivered into mammals to targeted organs, such as the kidney and the liver. These f-CNTs may be non-covalently linked or covalently linked to therapeutic agents. In particular, the application delivers carbon nanotube-therapeutic agent conjugates to a target organ, thereby preventing or reducing damages to the organ caused by other agents or procedure.
    Type: Application
    Filed: July 23, 2015
    Publication date: December 7, 2017
    Inventors: Michael R. MCDEVITT, Simone ALIDORI, Nima AKHAVEIN, David A. SCHEINBERG